Serological evidence that dry heating of clotting factor concentrates prevents transmission of non-A, non-B hepatitis.
A new test for antibodies specific for an agent causing non-A, non-B hepatitis (NANBH) was used to screen 45 children with coagulation disorders who received factor concentrates. It was found that the test results correlated with clinical evidence of NANBH and that heat treatment of concentrates (80 degrees C for 72 hours) appears to have prevented transmission of NANBH.
Skidmore
S J
SJ
Regional Virus Laboratory, East Birmingham Hospital, England.
Pasi
K J
KJ
Mawson
S J
SJ
Williams
M D
MD
Hill
F G
FG
D002648:Child; D005164:Factor IX / Q000627:therapeutic use*; D005169:Factor VIII / Q000627:therapeutic use*; D005260:Female; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control* / Q000635:transmission; D006525:Hepatitis, Viral, Human / Q000517:prevention & control*; D006358:Hot Temperature; D006801:Humans; D008297:Male; D014842:von Willebrand Diseases / Q000150:complications / Q000188:drug therapy
D005169:Factor VIII; D005164:Factor IX